Rankings
▼
Calendar
TCRX Q3 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TCRX
TScan Therapeutics, Inc.
$69M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
+139.4% YoY
Gross Profit
$2M
69.5% margin
Operating Income
-$37M
-1475.6% margin
Net Income
-$36M
-1422.1% margin
EPS (Diluted)
$-0.28
QoQ Revenue Growth
-18.4%
Cash Flow
Operating Cash Flow
-$32M
Free Cash Flow
-$34M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$262M
Total Liabilities
$118M
Stockholders' Equity
$144M
Cash & Equivalents
$170M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$1M
+139.4%
Gross Profit
$2M
$1M
+66.3%
Operating Income
-$37M
-$33M
-13.6%
Net Income
-$36M
-$30M
-19.5%
Revenue Segments
Reportable Segment
$3M
100%
← FY 2025
All Quarters
Q4 2025 →